

# Christoph Kornauth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7392852/publications.pdf>

Version: 2024-02-01

50  
papers

1,872  
citations

331259

21  
h-index

264894

42  
g-index

51  
all docs

51  
docs citations

51  
times ranked

3651  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelialâ€“mesenchymal transition in hepatocellular carcinoma. <i>Future Oncology</i> , 2009, 5, 1169-1179.	1.1	287
2	Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. <i>Nature Medicine</i> , 2013, 19, 481-487.	15.2	199
3	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 844-850.	2.1	177
4	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	0.6	132
5	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	2.2	130
6	Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions. <i>Food and Chemical Toxicology</i> , 2014, 72, 312-321.	1.8	77
7	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	7.7	77
8	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. <i>Blood</i> , 2017, 130, 2499-2503.	0.6	59
9	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. <i>Metallomics</i> , 2014, 6, 1616-1625.	1.0	58
10	Mineral oil in human tissues, Part II: Characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography. <i>Science of the Total Environment</i> , 2015, 506-507, 644-655.	3.9	50
11	[ <sup>68</sup> Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia. <i>Investigative Radiology</i> , 2018, 53, 403-408.	3.5	45
12	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018, 132, 2389-2400.	0.6	45
13	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(iv)-based anticancer agents. <i>Metallomics</i> , 2015, 7, 1256-1264.	1.0	42
14	Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. <i>Scientific Reports</i> , 2019, 9, 13783.	1.6	41
15	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	3.3	40
16	Behavior of platinum(IV) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. <i>Metallomics</i> , 2016, 8, 422-433.	1.0	39
17	Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. <i>Blood Advances</i> , 2017, 1, 352-356.	2.5	29
18	Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS. <i>Metallomics</i> , 2018, 10, 388-396.	1.0	29

#	ARTICLE	IF	CITATIONS
19	The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. <i>Kidney International</i> , 2015, 88, 332-340.	2.6	27
20	Extravasation of Pt-based chemotherapeutics – bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). <i>Metallomics</i> , 2015, 7, 508-515.	1.0	27
21	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	1.7	27
22	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. <i>Medicine (United States)</i> , 2015, 94, e2388.	0.4	24
23	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	0.6	22
24	Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells. <i>PLoS ONE</i> , 2018, 13, e0205195.	1.1	19
25	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. <i>Blood</i> , 2018, 132, 1936-1950.	0.6	18
26	Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. <i>Experimental Dermatology</i> , 2016, 25, 305-310.	1.4	16
27	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. <i>British Journal of Haematology</i> , 2019, 186, 448-459.	1.2	16
28	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. <i>Cancers</i> , 2020, 12, 9.	1.7	15
29	ECM Characterization Reveals a Massive Activation of Acute Phase Response during FSGS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2095.	1.8	14
30	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). <i>Hematological Oncology</i> , 2018, 36, 62-67.	0.8	12
31	STAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	1.7	12
32	Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. <i>Blood</i> , 2021, 138, 1345-1358.	0.6	12
33	Podocyte RNA sequencing reveals Wnt- and ECM-associated genes as central in FSGS. <i>PLoS ONE</i> , 2020, 15, e0231898.	1.1	10
34	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	1.7	9
35	The Phenotypic Characterization of the Human Renal Mononuclear Phagocytes Reveal a Co-Ordinated Response to Injury. <i>PLoS ONE</i> , 2016, 11, e0151674.	1.1	7
36	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. Nature Communications, 2021, 12, 7190.	5.8	7
38	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. Biology, 2021, 10, 1206.	1.3	3
39	Tissue distribution of epirubicin after severe extravasation in humans. Cancer Chemotherapy and Pharmacology, 2021, 88, 203-209.	1.1	2
40	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. Blood, 2019, 134, 807-807.	0.6	2
41	Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project. Blood, 2016, 128, 4252-4252.	0.6	2
42	Major response of PNH to an AML chemotherapy protocol. Annals of Hematology, 2018, 97, 1487-1488.	0.8	1
43	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood, 2019, 134, 3965-3965.	0.6	1
44	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. Blood, 2020, 136, 2-4.	0.6	1
45	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. Blood, 2019, 134, 4037-4037.	0.6	1
46	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia, 2021, 23, 1183-1191.	2.3	1
47	T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?. Frontiers in Oncology, 2022, 12, 805449.	1.3	1
48	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. Blood, 2017, 130, 855-855.	0.6	0
49	Abstract 2689: High-content imaging and single-cell analysis of drug response ex vivo is predictive of clinical outcome for hematologic cancer patients. , 2019, , .		0
50	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. Blood, 2020, 136, 40-41.	0.6	0